A novel nucleoside compound, its synthesis method, and its pharmaceutical applications
By synthesizing novel nucleoside compounds through a base modification strategy, the problems of drug resistance, cytotoxicity, and low bioavailability of traditional nucleoside drugs have been solved, achieving highly effective antiviral treatment.
Patent Information
- Application Number
- CN202611384479.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-08
- Publication Date
- 2026-11-17
AI Technical Summary
Traditional nucleoside antiviral drugs are prone to drug resistance, have cytotoxic effects on human cells, and are poorly lipid-soluble, resulting in low bioavailability and poor treatment efficacy.
Novel nucleoside compounds were synthesized through a base modification strategy. The reaction of 1-methoxy-2-deoxy-3,5-di-O-p-toluamide-L-furanose with phosphorus oxychloride, followed by further reaction with 6-chloro-1H-pyrazolo[3,4-d]pyrimidine-4-amine and an organic base, yielded novel bioactive nucleoside compounds.
It enhances the specific binding ability of drugs to viral polymerases, reduces toxicity to normal human cells, improves bioavailability, significantly inhibits drug resistance caused by viral mutations, prolongs the clinical lifespan of drugs, and improves the efficacy of antiviral treatment.
Smart Images

Figure CN123106800A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of organic chemistry, specifically relating to a method for preparing novel nucleoside compounds and their synthetic methods and pharmaceutical applications. Background Technology
[0002] Base modification strategy refers to drug design techniques that optimize the physicochemical properties and antiviral activity of nucleoside drugs by chemically modifying the purine or pyrimidine bases in nucleoside molecules, introducing different substituents, or altering the heterocyclic structure of the bases. This modification strategy is one of the most core and widely used strategies in the structural optimization and innovative development of nucleoside antiviral drugs, providing an important technical pathway to address the clinical challenges of traditional nucleoside drugs.
[0003] In base modification strategies, modified nucleoside molecules mimic the structure of natural nucleosides, allowing them to be specifically recognized by viral polymerases and incorporated into the viral nucleic acid chain, thereby exerting antiviral effects. Firstly, the modified bases form abnormal base pairs with the viral template bases, interfering with the normal replication and transcription of the viral genome. Subsequently, the abnormally paired nucleic acid chain cannot extend normally, leading to the termination of viral replication or inducing lethal mutations in viral RNA, reducing viral infectivity. Simultaneously, the modified bases can regulate the binding affinity of the nucleoside molecule to the viral polymerase, reducing interactions with enzymes in normal human cells and improving drug targeting. Remdesivir and entecavir are commonly used nucleoside antiviral drugs developed based on this strategy, playing a crucial role in the treatment of COVID-19 and hepatitis B virus infection.
[0004] Nucleoside antiviral drugs designed using base modification strategies have three modifiable sites: (1) Modification of pyrimidine bases: The 5-position of pyrimidine bases is the most commonly used modification site. Introducing substituents such as iodine, trifluoromethyl, and bromovinyl can significantly change the steric hindrance and electronic effects of the bases, enhancing the binding ability of the drug to viral polymerases. For example, iodoside and trifluuridine have obtained good antiviral activity through modification of this site; (2) Modification of purine bases: By modifying the 3- and 6-positions of purine bases, such as replacing the N atom at the 3-position with CH or introducing amino or halogen substituents, the broad-spectrum antiviral activity of the drug can be enhanced and drug resistance can be reduced; (3) Modification of heterocyclic bases: Replacing natural bases with heterocyclic structures such as 1,2,4-triazole rings can enhance the stability of the drug to nucleoside enzymes and prolong its half-life in vivo. Ribavirin is a typical example of this type of modification.
[0005] Currently, nucleoside antiviral drugs have become the mainstream of small-molecule broad-spectrum antiviral drugs. However, with the deepening of clinical application, many shortcomings of traditional nucleoside drugs have gradually become apparent. First, the high mutagenicity of viruses easily leads to mutations in base recognition sites, causing traditional nucleoside drugs to lose their antiviral activity and develop drug resistance, which is one of the main challenges in clinical treatment. Second, traditional nucleoside drugs have low selectivity for viral polymerases and easily bind to nucleic acid polymerases in normal human cells, interfering with normal cell metabolism and producing certain cytotoxicity. Finally, some unmodified nucleoside drugs have poor lipid solubility, low in vivo absorption efficiency, and low bioavailability, requiring higher dosages to achieve therapeutic effects, further increasing the risk of adverse reactions.
[0006] In view of the shortcomings of the prior art, this invention designs and synthesizes a series of novel base-modified nucleoside antiviral drugs through a base modification strategy. These drugs effectively improve the lipid and water solubility of the drugs, enhance bioavailability, strengthen the specific binding ability of the drugs to viral polymerases, reduce toxicity to normal human cells, and improve targeting. At the same time, they effectively inhibit the development of drug resistance caused by viral mutations, prolong the clinical lifespan of the drugs, and significantly improve the antiviral therapeutic effect, providing new candidate drugs for the clinical treatment of viral infectious diseases. Summary of the Invention
[0007] To overcome the aforementioned technical deficiencies, this invention provides a method for preparing novel nucleoside compounds, their synthetic method, and their pharmaceutical applications. Using 1-methoxy-2-deoxy-3,5-di-O-p-toluyl-L-furanose 1 and phosphorus oxychloride 2 as raw materials, a multi-step continuous reaction involving protecting group addition, chlorination, C-glycosylation, and deprotection is employed to obtain novel nucleoside compounds containing biological activity. This novel nucleoside drug effectively reduces cytotoxicity and improves cell selectivity; this class of drugs exhibits strong physiological activity against HBV DNA replication.
[0008] The novel nucleoside compound of this invention has the following general structural formula:
[0009]
[0010] Wherein: R1 is a nitrogenous base, specifically selected from... , , or R2 is selected from OH or H.
[0011] This invention also provides a method for synthesizing the above-mentioned novel nucleoside analogue, comprising the following steps:
[0012] (1) 1-Methoxy-2-deoxy-3,5-di-O-p-toluyl-L-furanose 1 reacts with phosphorus oxychloride 2 at high temperature to give intermediate 3;
[0013] (2) Intermediate 3 reacts with compound 4 in an organic solvent in the presence of an organic base to obtain intermediate 5;
[0014] (3) Intermediate 5 reacts with an organic base in an organic solvent to obtain a novel nucleoside compound 6;
[0015] The reaction equation is as follows:
[0016]
[0017] Wherein: Tol is p-toluyl, compound 4 is R1H, and R2 is selected from OH or H.
[0018] Furthermore, in steps (2) and (3), the organic base is selected from potassium tert-butoxide or sodium methoxide.
[0019] Furthermore, in step (1), the reaction temperature is 100~120℃, and the molar ratio of compound 1 to phosphorus oxychloride is 1:(20~25).
[0020] Further, in step (2), the organic solvent is selected from acetonitrile or tert-butanol; the reaction temperature is 25~50℃, and the molar ratio of intermediate 3, compound 4 and organic base is 1:(1.5~2.5):(2.5~3.5).
[0021] Further, in step (3), the organic solvent is selected from methanol or a mixture of methanol and water, the reaction temperature is room temperature, and the molar ratio of intermediate 5 to organic base is 1:(1.5~2.0).
[0022] The present invention also provides the application of the aforementioned novel nucleoside prodrug in the preparation of antiviral drugs, wherein the virus is HBV virus.
[0023] Furthermore, in the above technical solution, the HBV virus-corresponding cells are selected from HepG2 / 2.2.15 cells that can sustainably and stably express HBV virus.
[0024] The present invention has the following beneficial effects:
[0025] 1. This invention employs a few-step synthesis method, the raw materials are readily available, the synthesis steps are simple, and the reaction conditions are mild.
[0026] 2. This invention designs and synthesizes a series of novel nucleoside compounds through a C-glycosylation strategy, which enhances their stability, improves cell selectivity, increases bioavailability, and greatly improves therapeutic efficacy. Attached Figure Description
[0027] Figure 1 The steps for testing the bioactivity of the novel nucleoside compounds in Example 4 are as follows;
[0028] Figure 2 The relative expression level of HBV DNA in HepG2 / 2.2.15 cells was determined by the novel nucleoside compound in Example 4.
[0029] Figure 3 The EC50 values for inhibiting DNA replication in HepG2 / 2.2.15 cells were calculated based on the detection of different concentrations of the novel nucleoside compound in Example 4, which was used to assess HBV activity. 50 ;
[0030] Figure 4 The CC was calculated by using the MTT assay to detect the cytotoxicity of different concentrations of novel nucleoside compounds in Example 4. 50 . Detailed Implementation
[0031] The present invention will be further illustrated below with specific examples. These embodiments should be understood as illustrative only and not as limiting the scope of protection of the present invention. After reading the description of the present invention, those skilled in the art can make various alterations or modifications to the present invention, and these equivalent changes and modifications also fall within the scope defined by the claims of the present invention.
[0032] Example 1
[0033]
[0034] Under normal temperature and pressure, 1-methoxy-2-deoxy-3,5-di-O-p-toluyl-L-ribofuranoside 1 (1.48 g, 10 mmol) and phosphorus oxychloride 2 (21.4 mL, 230 mmol) were added to a 50 mL pressure-resistant tube, followed by reflux at 110 °C and atmospheric pressure for 17 hours, with the reaction monitored by TLC. After compound 1 reacted completely, the mother liquor was cooled. Then, ice-cold 2N sodium hydroxide solution was slowly added dropwise to pH 6-7 under an ice-water bath, with continuous stirring to ensure complete quenching. The mother liquor was then extracted with ethyl acetate (50 mL × 2), and all organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated by rotary evaporation under reduced pressure, and the residue was purified by thin-layer chromatography (volume ratio, petroleum ether:ethyl acetate = 3:1) to obtain intermediate 3.
[0035] At 30°C, 6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine 4 (508.74 mg, 3 mmol) and potassium tert-butoxide (673.26 mg, 6 mmol) were added to a 50 mL round-bottom flask, followed by tert-butanol (10 mL). The mixture was stirred at 30°C for 2 hours. Then, intermediate 3 (777.7 mg, 2 mmol) was dissolved in acetonitrile (3 mL). The reaction temperature was then raised to 50°C. After the solution stabilized at 50°C for 3 minutes, the acetonitrile solution of intermediate 3 was slowly added dropwise. The reaction mixture was then stirred continuously at 50°C for 5 hours. The reaction was monitored by TLC until it was complete. The reaction system was cooled to room temperature, and 5 mL of purified water was added dropwise while stirring to quench the reaction. After complete quenching, ethyl acetate (20 mL × 4) was added to extract the reaction and separate the organic phase. All organic phases were combined and washed with saturated sodium chloride solution (30 mL). All organic phases were combined and dried over anhydrous sodium sulfate, filtered, and concentrated by rotary evaporation under reduced pressure. The residue did not need to be purified and was used directly in the next reaction.
[0036] Under ambient temperature and pressure, 25 mL of a methanol solution of sodium methoxide (3 mg / mL) was added to the residue of intermediate 5. The mixture was stirred for 2 hours under ambient temperature and pressure, and the reaction was monitored by TLC. The reaction was complete. The mother liquor was directly concentrated to dryness by rotary evaporation under reduced pressure, and the residue was purified by thin-layer chromatography. The eluent was dichloromethane / methanol (100:1 to 10:1). The product was 6, in two configurations: the β configuration (ZL-698) was a pale yellow solid (21 mg), and the α configuration (ZL-699) was a yellow oil (7 mg). The overall yield of the two steps was 16.7%. β configuration: 1 H NMR (400MHz, DMSO-d 6 ) δ 8.02 (s, 1H, ), 6.33 (dd, J = 4.4,7.2Hz, 1H), 5.64(d, J = 7.6Hz, 1H), 4.69-4.66 (m, 1H), 3.91-3.88 (m, 1H), 3.48-3.44 (m, 1H), 2.28-2.61 (m, 1H), 2.68-2.44 (m, 3H); 13 C { 1 H} NMR (100 MHz, DMSO-d 6 ) δ 165.3, 159.5, 156.5, 133.8, 98.0, 87.9, 84.2, 71.6, 63.0, 38.2. α configuration 1 H NMR (400MHz, DMSO-d 6) δ 7.98 (s, 1H, ), 6.40 (t, J = 6.8Hz, 1H), 5.20 (d,J = 4.4Hz, 1H), 4.40-4.36 (m, 1H), 4.71 (t, J = 6.0Hz, 1H), 3.78-3.74 (m, 1H)3.51-3.45 (m, 1H), 2.79-2.73 (m, 1H), 2.47-2.45 (m, 2H); 13 C { 1 H} NMR (100MHz, DMSO-d 6 ) δ 165.1, 159.2, 156.3, 133.4, 97.8, 87.6, 84.0, 71.3, 62.8,37.9.
[0037] Example 3
[0038] A series of compounds were synthesized using the same method described above, with the following structural formulas:
[0039]
[0040]
[0041]
[0042]
[0043] Example 4
[0044] This embodiment describes the detection process and results of the compound described in the foregoing embodiments inhibiting HBV virus replication within cells. Unless otherwise specified, all materials and consumables listed in this embodiment are commercially available. Cells and viruses are sourced from cell and microbial resource banks of CTCC or other relevant institutions. The experimental methods in this embodiment follow standard molecular biology, cell biology, or virology procedures, which researchers in the field can easily understand and operate. The specific steps are as follows:
[0045] 1. Cells:
[0046] The HepG2 / 2.2.15 cell line (with inserted HBV ayw, D subtype, 3182 bp, stably expressed) was constructed as follows: HepG2 cell lines were used as hosts for human hepatocellular carcinoma HepG2 cells. A full-length 3182 bp HBV D subtype ayw serotype diploid recombinant plasmid (containing the G418 resistance marker) was introduced via liposome transfection. After transfection, the cells were continuously screened with 400 μg / mLG418 for 2–3 weeks to obtain a positive cell pool. Monoclonalization using limiting dilution was then performed to select stable clones (2.2.15) integrating the HBV genome. PCR, sequencing, and antigen detection confirmed that HBV (ayw / D / 3182 bp) was stably integrated into the cell genome, continuously expressing HBsAg and HBeAg and replicating viral particles, ultimately constructing the HepG2 / 2.2.15 cell line with stable HBV expression. Culture conditions: DMEM + 10% FBS + 1% double Pen-Strep + 380 μg / ml G418 + 0.2% L-Glutamine + 0.2% non-essential amino acids.
[0047] Note: HBV DNA is carried by these cells as an integrated chromosomal sequence and also in free form as loose circular, covalently closed, and incomplete copies of the HBV genome. Most HBV DNA appears to exist in covalently closed circular (ccc) and nicked recircular forms, as well as incomplete copies of the genome.
[0048] 2. Main reagents:
[0049] DMEM (Gibco, cat: C11995500BT);
[0050] Fetal bovine serum FBS (Gibco, cat:10270-106);
[0051] Double Pen-Strep (10,000U / mL) (M&C gene biotechnology, cat: G2723M3);
[0052] Anti-HBV positive drugs: tenofovir disoproxil fumarate (TDF) and mofoxetine mesylate (GLS4).
[0053] Tguide Smart Universal Genomic DNA Extraction Kit (TIANGEN, mat:4995 051)
[0054] 3. Experimental steps:
[0055] Step 1, as follows Figure 1 As shown, preliminary screening of compounds showed that they inhibited HBV activity:
[0056] The experiment included two control groups: a positive control group (treated with 10 µM TDF and 10 µM MGLS4 at final concentrations) and a virus control group (treated with only DMSO, without the compound). The experimental group consisted of HepG2 / 2.2.15 cells, 3 × 10⁻⁶ cells. 5 Cells / well, 24-well plate, 375 μL / well; 12-16 h after cell seeding, once cells have fully adhered, discard the original culture medium and add 375 μL of culture medium containing the test compound or positive control drug to achieve a final concentration of 25 µM for the test compound and 10 µM for the positive control drug; 4 days after incubation at 37°C, add 125 μL of culture medium containing the test compound (25 µM) or positive control drug (10 µM); 6 days after incubation at 37°C, add 125 μL of culture medium containing the test compound (25 µM) or positive control drug (10 µM); 8 days after incubation at 37°C, collect cells and culture supernatant; extract DNA from samples using an automated nucleic acid extractor, and determine the inhibition rate of the compound against HBV virus using qPCR; detect the two viral antigens using enzyme-linked immunosorbent assay (ELISA) to determine the viral protein secretion level.
[0057] Additional information: qPCR testing:
[0058] Primer: F Primer: 5'-CCTAGTAGTCAGTTATGTCAAC-3'
[0059] R Primer:5'-TCTATAAGCTGGAGGAGTGCGA-3'
[0060] Amplified gene: C gene
[0061] Amplification conditions: 95℃, 10 min;
[0062] 95℃, 15s; 60℃, 30s; 72℃, 30s×40
[0063] Detection results: Initial screening results of anti-HBV activity at a single concentration (25 µM) are shown below. Figure 2 The compound concentration was 25 µM, while the control drugs TDF and GLS4 had concentrations of 10 µM.
[0064] Conclusion: At a concentration of 25 µM, the expression level of HBV DNA by compound ZL-698 was significantly different from that of the DMSO control group. The relative expression level of HBV DNA by compound ZL-698 reached 33%, demonstrating a highly significant inhibitory effect on DNA replication.
[0065] Step 2: Replace the 25 μM test compound in Step 1 with test compounds at final concentrations of 0.0016 μM, 0.008 μM, 0.04 μM, 0.2 μM, 1 μM, 5 μM, and 25 μM. Following Step 1, calculate the relative HBV infection luciferase activity as: compound fluorescence value / virus control fluorescence value. Then, based on the relative HBV infection luciferase activity, use GraphPad Prism software to determine the EC50 for inhibiting viral replication. See [link to results]. Figure 3 .Depend on Figure 3 It can be seen that the EC50 of compound ZL-698 is 0.746 μM.
[0066] Step 3: MTT assay for cytotoxicity: 5 × 10⁻⁶ 4 Cells were seeded in 96-well cell culture plates containing 100 μL of cell culture medium; 100 μL of compound solution was added; each concentration was repeated in triplicate; a control without the compound was also included; after 72 h of cell culture, 100 μL of supernatant was discarded, 20 μL of MTT (5 mg / mL) was added, and the cells were incubated at 37°C for 4 h; after centrifugation, 100 μL of supernatant was discarded, 100 μL of DMSO was added, and the cells were incubated at room temperature in the dark, shaken for 15 minutes until the blue formazene dissolved; the cell viability was measured using a microplate reader with OD595 and OD630 as the reference wavelength, and the CC was calculated based on the cell viability. 50 For details, please see the results. Figure 4 ,Depend on Figure 4 It can be seen that CC 50 >500μM.
[0067] Step 4: Calculation of the drug's antiviral activity selectivity index: Selective Index (SI) = CC 50 / EC 50 >670.241μM.
[0068] The above description is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and inventive concept of the present invention, should be covered within the scope of protection of the present invention.
Claims
1. A novel nucleoside compound, characterized in that, The general structural formula is as follows: Where R1 is a nitrogenous base, specifically selected from... , , or R2 is selected from OH or H.
2. The method for synthesizing the novel nucleoside compound according to claim 1, characterized in that, Includes the following steps: (1) Compound 1 reacts with phosphorus oxychloride 2 at high temperature to give intermediate 3; (2) Intermediate 3 reacts with compound 4 in an organic solvent in the presence of an organic base to obtain intermediate 5; (3) Intermediate 5 reacts with an organic base in an organic solvent to give a novel nucleoside compound 6; the reaction equation is as follows: Where: Tol is p-toluyl, compound 4 is R1H, and R2 is selected from OH or H.
3. The method for synthesizing the novel nucleoside compound as described in claim 2, characterized in that: In steps (2) and (3), the organic base is selected from potassium tert-butoxide or sodium methoxide.
4. The method for synthesizing the novel nucleoside compound as described in claim 2, characterized in that: In step (1), the reaction temperature is 105~120℃, and the molar ratio of compound 1 to phosphorus oxychloride is 1:(20~25).
5. The method for synthesizing the novel nucleoside compound as described in claim 3, characterized in that: In step (2), the organic solvent is selected from acetonitrile or tert-butanol; the reaction temperature is 25~50℃; and the molar ratio of intermediate 3, compound 4 and organic base is 1:(1~2):(2.5~3.5).
6. The method for synthesizing the novel nucleoside compound as described in claim 3, characterized in that: In step (3), the organic solvent is selected from methanol or a mixture of methanol and water, the reaction temperature is room temperature, and the molar ratio of intermediate 5 to organic base is 1:(1.5~2.0).
7. The application of the novel nucleoside compound as described in claim 1 in the preparation of antiviral drugs, characterized in that: The virus in question is HBV.
8. The application as described in claim 7, characterized in that: The HBV virus-corresponding cells were selected from Hep G2 / 2.2.15 cells.
